Biotech Series B Investors & VC Firms
724 firms in this list, with a median first check of $500K. 165 of them lead rounds. Generated from verified public data and updated continuously.
Optum Ventures
BostonSeed–Growth
35 people
Catalio Capital Management, LP
New YorkSeed–Late Stage
37 people
Metaplanet
TallinnSeed–Series B$500K – $10M
4 people
Prosperity7 Ventures
DhahranSeries A–Growth
43 people
South Park Commons
San FranciscoPre-Seed–Late Stage$1M – $10M
13 people
Sanofi Ventures
CambridgeSeed–Series B$5M
20 people
OUP (Osage University Partners)
Bala CynwydPre-Seed–Late Stage$1M – $20M
21 people
UpHonest Capital
Silicon ValleyPre-Seed–Series B$50K – $1M
24 people
Casdin Capital
New YorkSeed–Series C
38 people
Bain Capital Life Sciences
BostonSeries B–Late Stage
31 people
Manta Ray Ventures
LondonPre-Seed–Growth
8 people
S32
Palo AltoSeries A–Late Stage
30 people
Johnson & Johnson Innovation – JJDC
New BrunswickSeed–Growth
42 people
Nazca
Mexico CityPre-Seed–Late Stage
32 people
Pfizer Venture Investments
Seed–Late Stage$5M – $20M
16 people
AgFunder
San FranciscoSeed–Series C$10K – $5M
23 people
Taiwania Capital
TaipeiSeed–Growth
49 people
Eurazeo
ParisSeed–Late Stage
35 people
Vida Ventures
Los AngelesPre-Seed–Late Stage
44 people
Hyundai Venture Investment Corporation
SeoulSeed–Series B$500K – $2M
OneVentures
SydneySeed–Growth$3.3M – $13.2M
40 people
redalpine
ZugSeed–Growth$108K – $2.2M
28 people
b2venture
BerlinPre-Seed–Series B$270K – $5.4M
36 people
Lightstone Ventures
Portola ValleyPre-Seed–Series C
31 people
Related lists
Series B Investors & VC Firms (2951)Biotech Investors & VC Firms (2483)Biotech Seed Investors & VC Firms (2027)Series B Investors & VC Firms in North America (1738)Biotech Series A Investors & VC Firms (1627)Biotech Investors & VC Firms in North America (1601)Series B Investors & VC Firms in United States (1573)Biotech Investors & VC Firms in United States (1450)SaaS Series B Investors & VC Firms (1075)Series B Investors & VC Firms in Europe (1073)
Data sourced from public filings and firms' own websites — see our methodology.










































































































